Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 DiabetesDigestive System DiseaseLiver DiseasesFatty LiverMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-Alcoholic Fatty Liver DiseaseHypoglycemic AgentsPhysiological Effects of DrugsSodium-Glucose Cotransporter 2 Inhibitors
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 60
- Registration Number
- NCT03646292
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, Seoul, Korea, Republic of
Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 400
- Registration Number
- NCT03566225
- Locations
- 🇪🇬
Ain Shams Univerisity, Cairo, Egypt
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 72
- Registration Number
- NCT03501277
- Locations
- 🇷🇺
Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways, Yaroslavl, Russian Federation
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- The University of Texas at Arlington
- Target Recruit Count
- 28
- Registration Number
- NCT03471117
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸University of Texas at Arlington, Arlington, Texas, United States
Insulin Signaling in Skeletal Muscle
- Conditions
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Wayne State University
- Registration Number
- NCT03452267
Study of Pioglitazone in Sporadic Inclusion Body Myositis
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 19
- Registration Number
- NCT03440034
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Study of NGM313 in Obese Participants
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- NGM Biopharmaceuticals, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT03298464
- Locations
- 🇺🇸
Prosciento, Chula Vista, California, United States
Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 3
- Registration Number
- NCT03231033
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 250
- Registration Number
- NCT03109288
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pioglitazone Therapy for Chronic Granulomatous Disease
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 3
- Registration Number
- NCT03080480
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.